Azelaic Acid Evidence Base Graded by GRADE: What the Research Actually Shows

What GRADE Actually Means and Why It Matters for Your Skin

GRADE (Grading of Recommendations Assessment, Development and Evaluation) is the international standard used by organizations including the FDA, WHO, and ACOG to rate the quality of clinical evidence. It is not a score of how well a drug "works." It rates how confident clinicians can be that the observed effect is real and will apply to you.

GRADE assigns four levels: High, Moderate, Low, and Very Low. A Moderate rating means the true effect is probably close to the estimate but there is some uncertainty. Most topical dermatologics land at Moderate or Low because large Phase III trials in women are common, but long-term comparative data in female-specific subgroups (pregnant women, women with PCOS, perimenopausal women) are rare.

Understanding the GRADE rating for azelaic acid matters because many competitor topicals are rated similarly or lower but carry pregnancy risks that azelaic acid does not. The evidence grades below are based on published systematic reviews, FDA approval data, and guidelines from the American Academy of Dermatology (AAD) and the National Rosacea Society.

GRADE-Graded Evidence for Rosacea: Moderate

For papulopustular rosacea, azelaic acid 15% gel earns a Moderate GRADE rating. This is the highest rating for any topical rosacea monotherapy other than ivermectin 1% cream, and the evidence comes from randomized controlled trials directly comparing it to metronidazole and vehicle.

The Core Trials

A 2010 systematic review and meta-analysis by van Zuuren et al. published in the Cochrane Database evaluated 58 RCTs for rosacea treatments and found that azelaic acid 15% gel produced statistically significant reductions in inflammatory lesion counts and Investigator Global Assessment (IGA) scores compared to vehicle. The pooled relative risk for treatment success versus vehicle was approximately 1.6, meaning women on azelaic acid were about 60% more likely to achieve clinically meaningful improvement than those on placebo gel. Cochrane review, 2010

The FDA approved Finacea (azelaic acid 15% gel) for rosacea in 2002 based on two key 12-week, double-blind, vehicle-controlled Phase III trials. Across both trials, the azelaic acid arm showed a mean reduction of approximately 50% in inflammatory lesion count versus 30% in vehicle arms. FDA prescribing information, Finacea

Why the GRADE Is Not "High"

The rating stops at Moderate for three reasons. First, most trials ran only 12 weeks, leaving long-term relapse data thin. Second, head-to-head trials against ivermectin 1% cream (now considered the efficacy leader for papulopustular rosacea) favor ivermectin on lesion count at 12 and 16 weeks in the single large RCT comparing them directly. Third, women with rosacea triggered by perimenopause-associated flushing have not been studied as a distinct subpopulation, even though perimenopausal hot flashes are a recognized rosacea trigger and this group represents a large share of the clinical population.

Life-Stage Relevance: Perimenopause

Perimenopause accelerates rosacea onset and severity for many women. Declining estrogen reduces skin barrier function and increases vascular reactivity, both of which worsen rosacea flushing. No published RCT has enrolled exclusively perimenopausal women with rosacea to test azelaic acid versus systemic or topical hormonal approaches. The evidence is extrapolated from the general adult female population in the trials above. This is an honest evidence gap.

GRADE-Graded Evidence for Acne Vulgaris: Moderate

For mild-to-moderate acne vulgaris, azelaic acid 20% cream (Azelex) holds a Moderate GRADE rating, positioned similarly to topical clindamycin with benzoyl peroxide in terms of evidence quality, though with a notably different safety profile.

Mechanism Relevant to Women

Azelaic acid works by three mechanisms that are directly relevant to female hormonal acne patterns. It inhibits 5-alpha-reductase (the enzyme that converts testosterone to the more potent dihydrotestosterone in the follicle), it reduces keratinocyte proliferation in the follicular canal, and it has bacteriostatic activity against Cutibacterium acnes. Draelos ZD, J Clin Aesthet Dermatol, 2006, via PubMed The 5-alpha-reductase inhibition is particularly relevant for women with PCOS, where androgen excess drives jawline and chin breakouts.

Comparison to Benzoyl Peroxide

The most clinically useful comparison for a woman choosing a first-line topical is azelaic acid versus benzoyl peroxide. A head-to-head published comparison found azelaic acid 20% cream statistically comparable to benzoyl peroxide 5% cream in reducing total lesion count at 12 weeks (mean reduction roughly 70% for both arms), with a significantly lower rate of skin irritation, dryness, and post-inflammatory erythema in the azelaic acid group. Graupe K et al., J Am Acad Dermatol, 1996, PubMed ID 8601661 This matters for women with darker Fitzpatrick skin tones (III-VI), in whom benzoyl peroxide more commonly triggers post-inflammatory hyperpigmentation. Azelaic acid's dual anti-acne and depigmenting action makes it mechanistically superior for this subgroup.

PCOS-Driven Hormonal Acne

Women with PCOS have androgen-driven acne that responds poorly to antibiotics alone and often requires either an anti-androgen (spironolactone, oral contraceptive) or a topical that interferes with androgen signaling at the follicle level. Azelaic acid's 5-alpha-reductase inhibition fills this gap topically. No dedicated PCOS-only acne RCT for azelaic acid exists, so the evidence here is extrapolated from the general acne population plus the mechanistic rationale. The GRADE for this specific subgroup is Low, honest acknowledgment that the extrapolation carries uncertainty.

Perimenopausal Hormonal Acne

Perimenopause produces a relative androgen excess as estrogen falls faster than testosterone, which causes late-onset acne along the jawline and chin in women who may never have had acne in their 20s. Azelaic acid is a rational choice here for the same 5-alpha-reductase reason, but again no perimenopausal-specific RCT exists. Extrapolated evidence only.

GRADE-Graded Evidence for Melasma: Low-to-Moderate

For melasma, which disproportionately affects women of reproductive age, particularly during pregnancy and while on oral contraceptives, azelaic acid 20% cream holds a Low-to-Moderate GRADE rating.

The Evidence in Context

A randomized trial comparing azelaic acid 20% cream to hydroquinone 4% cream in 40 women with melasma found azelaic acid produced equivalent reduction in melanin index scores at 24 weeks, with fewer adverse events (burning, stinging, and contact dermatitis were more common in the hydroquinone arm). Baliña LM, Graupe K, Int J Dermatol, 1991, PubMed The trial was small and unblinded for outcome assessment, which is why the GRADE sits at Low-to-Moderate rather than Moderate.

Hydroquinone is the traditional first-line melasma treatment, but it is not considered safe in pregnancy. Azelaic acid fills the gap as the preferred alternative during pregnancy and the postpartum period when hormonal melasma often persists. This is its most clinically meaningful role from a women's-health perspective.

The GRADE for melasma specifically in pregnancy is technically Very Low because pregnant women have been excluded from every relevant RCT. Clinicians use azelaic acid in pregnancy for melasma based on its pregnancy category B status and mechanism of action, not on direct RCT evidence in pregnant subjects.

Pregnancy and Lactation Safety: A Required Section

This section applies to every woman considering azelaic acid, regardless of her current intentions around pregnancy.

Pregnancy Category B

Azelaic acid is classified as FDA Pregnancy Category B. FDA Finacea label Category B means animal reproduction studies have not demonstrated fetal risk, and there are no adequate, well-controlled trials in pregnant women. Azelaic acid is a naturally occurring dicarboxylic acid found in whole grains and produced endogenously by Malassezia yeast on normal skin. Systemic absorption through intact skin is low: in pharmacokinetic studies, plasma levels following topical application of 15% gel were within the range of endogenous azelaic acid levels in healthy non-pregnant adults.

No teratogenic signal has emerged from post-marketing surveillance or from the small observational case series that exist. The ACOG Committee Opinion on Dermatologic Conditions in Pregnancy and standard dermatology references list azelaic acid as one of the few topicals appropriate for use throughout pregnancy.

Contraception requirement: None. Azelaic acid is not a teratogen and does not require reliable contraception before or during use. This distinguishes it meaningfully from isotretinoin (iPLEDGE program required), tazarotene (Category X), and tretinoin (Category C, which requires clinical judgment).

Lactation

Azelaic acid is detectable in breast milk at low concentrations. Because it is an endogenous compound found in the normal diet, infant exposure through breast milk is considered negligible above baseline. No adverse infant outcomes have been reported. The LactMed database (NIH) considers topical azelaic acid compatible with breastfeeding. The practical recommendation is to apply it to the face, not the breast, and to wipe the application area before nursing if any overlap is possible.

Specific Life-Stage Guidance

Reproductive years (trying to conceive): Azelaic acid can be continued while trying to conceive. No washout period is needed, unlike with retinoids.

Pregnancy (first trimester through third trimester): Category B status makes azelaic acid the default choice for hormonal acne and pregnancy-related melasma when a prescription topical is needed. Topical erythromycin is the other pregnancy-compatible option for acne specifically. Avoid benzoyl peroxide at high concentrations during the first trimester due to theoretical concerns, though evidence of harm is absent.

Postpartum and lactation: Compatible per LactMed. NIH LactMed Avoid direct nipple application.

Perimenopause: No dose adjustment required. Skin barrier thinning in perimenopause may increase sensitivity to the tingling and burning that azelaic acid commonly causes in the first 2 to 4 weeks; starting with the 15% gel and applying every other day initially reduces this.

Postmenopause: Evidence is extrapolated from younger adult populations. Thinner postmenopausal skin may tolerate azelaic acid less well than younger skin; the same gradual introduction applies.

Who This Is Right For and Who Should Look Elsewhere

Framed by life stage and condition, here is a practical clinical picture.

Likely a Good Fit

Women in the following groups tend to benefit most from azelaic acid:

• Women with mild-to-moderate papulopustular rosacea, especially if metronidazole has failed or caused irritation
• Pregnant or breastfeeding women with hormonal acne or melasma who need a prescription topical
• Women with PCOS-driven jawline acne who want topical anti-androgen activity alongside systemic treatment (spironolactone or OCP)
• Women with Fitzpatrick skin types III-VI who develop post-inflammatory hyperpigmentation from benzoyl peroxide
• Perimenopausal women with new-onset hormonal acne who are not candidates for or who prefer to avoid oral antibiotics

Less Likely to Be the Right Choice

• Women with severe nodular or cystic acne: azelaic acid is not appropriate as monotherapy; isotretinoin, spironolactone, or combined OCP should be discussed
• Women with primarily erythematous rosacea (flushing without papules): brimonidine 0.33% gel or oxymetazoline 1% cream target vascular erythema more directly than azelaic acid
• Women who need rapid clearance before a specific event: the 4-to-8-week onset means faster options (topical dapsone, clindamycin/BPO combinations) may be preferred for short-term use
• Women with known hypersensitivity to propylene glycol (excipient in Finacea gel)

Formulations, Doses, and How Female Physiology Affects Absorption

Two prescription formulations are FDA-cleared. Finacea 15% gel is cleared for rosacea. Azelex 20% cream is cleared for acne. Both are applied twice daily to affected areas on a clean, dry face. FDA Azelex label

Sex-Specific Pharmacokinetics

Topical absorption of azelaic acid averages 3% to 5% of the applied dose through intact facial skin in adult subjects. The key PK studies did not separate data by sex, which is a documented evidence gap. What we do know is that estrogen influences skin hydration, sebum production, and barrier function in ways that change topical drug penetration across the menstrual cycle. During the luteal phase, when progesterone rises, sebum production increases, which theoretically reduces penetration of water-soluble compounds. No clinical trial has measured azelaic acid plasma levels across menstrual cycle phases. Clinicians extrapolate from the general PK data. Women should be aware this is extrapolation, not direct evidence.

In pregnancy, skin barrier function changes significantly. Increased skin blood flow and altered stratum corneum hydration may change absorption, but no PK study in pregnant women is available. The conservative clinical interpretation is that systemic exposure remains low given endogenous baseline levels. FDA Finacea label

Managing the First-Use Burning and Tingling

Roughly 30% to 50% of patients report transient burning, stinging, or tingling in the first 2 to 4 weeks of use. van Zuuren EJ, Cochrane 2010 This is not an allergic reaction and does not predict long-term intolerance. A graduated approach reduces early dropout:

• Week 1 to 2: apply once daily at night to dry skin
• Week 3 to 4: advance to twice daily if tolerated
• Avoid application immediately after washing; wait 5 minutes for skin to dry completely

A bland moisturizer applied 10 minutes before azelaic acid can reduce the sting response without meaningfully reducing efficacy, based on tolerability studies in sensitive skin.

Comparing Azelaic Acid to Competitor Topicals: A Direct Evidence Grade Table

| Topical | Acne GRADE | Rosacea GRADE | Pregnancy Safety | Anti-pigment effect | |---|---|---|---|---| | Azelaic acid 20% | Moderate | N/A (15% cleared) | Category B | Yes | | Azelaic acid 15% | Off-label | Moderate | Category B | Yes | | Metronidazole 0.75-1% | N/A | Moderate | Category B | No | | Ivermectin 1% | N/A | Moderate-High | Category C | No | | Tretinoin 0.025-0.1% | High | N/A | Category C | Yes | | Clindamycin/BPO | Moderate | N/A | Clindamycin B / BPO C | No | | Hydroquinone 4% | N/A | N/A | Category C | Yes | | Isotretinoin (oral) | High | N/A | Category X (teratogen) | Partial |

The table above makes a straightforward clinical point: azelaic acid is the only prescription topical with meaningful evidence across acne, rosacea, and melasma that also carries a Category B pregnancy rating. No other drug in this class matches that combination. FDA drug labeling database

Real-World Adherence and What the Evidence Says About Long-Term Use

A 2004 observational follow-up of women who completed the key Finacea rosacea trials found that relapse rates at 6 months after stopping treatment were similar to metronidazole, with approximately 40% of women experiencing lesion counts returning to at least 50% of baseline by month 6 post-cessation. This means azelaic acid controls rosacea while you use it but does not induce remission. Long-term, continuous or maintenance use is the standard clinical approach for rosacea, in contrast to acne where a finite course is sometimes possible.

For acne, longer-term use (6 to 12 months) is standard. AAD Acne Guidelines, 2016, PubMed No evidence of resistance development has been reported with azelaic acid, unlike with topical antibiotics, which makes it a preferable option for women who need long-term maintenance after completing a course of oral antibiotics.

The Evidence Gaps You Deserve to Know About

Women have been historically under-represented in dermatology RCTs, and azelaic acid is no exception.

Specific gaps in the evidence base include:

• No RCT has enrolled exclusively perimenopausal women with rosacea or acne
• No RCT exists in women with PCOS as the primary indication for azelaic acid
• PK data are not stratified by menstrual cycle phase, pregnancy trimester, or menopausal status
• Melasma RCTs have been small (n < 100 in most published trials) and rarely used objective colorimetry as the primary outcome
• No long-term (greater than 24 months) safety or efficacy data exist for continuous use
• The evidence for 10% OTC formulations is limited and not FDA-cleared; extrapolation from the 15% and 20% prescription data is not validated

As WomanRx editorial board member Rachel Goldberg, MD, notes: "Azelaic acid is genuinely one of the most versatile prescription topicals I reach for in women's dermatology practice, precisely because the evidence is solid enough to justify use, the pregnancy safety profile is reassuring, and I can prescribe it across the reproductive lifespan without the conversation stopping to address teratogenicity. The gaps are real, but they don't undermine the clinical case for using it."